We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arkema Expands Shanghai R&D Center to Boost Innovation
Read MoreHide Full Article
Key Takeaways
Arkema expands its Shanghai R&D Center to accelerate innovation and strengthen customer ties across Asia.
The expansion adds 20% more lab space and new collaborative facilities, including an interactive showroom.
Arkema targets high-growth markets like energy, electronics and mobility through sustainable materials R&D.
Arkema S.A. (ARKAY - Free Report) has officially opened the expansion of its Shanghai R&D Center in China, strengthening its capabilities to foster innovation, enable synergies within teams and increase engagement with customers in Asia. The investment aligns with the company's global research and development strategy.
The expansion increases laboratory space by around 20% and introduces new collaborative facilities, including an interactive showroom to showcase Specialty Materials solutions. The upgraded center will bring together Arkema’s expertise in the materials business and interaction with the local R&D ecosystem to jointly develop with customers and accelerate innovation in high-performance and sustainable materials.
Established in 2011 as Bostik's Asia Technology Center, the Shanghai facility has developed expertise in materials synthesis, formulation development and application validation. Its innovations are used in high-speed rail, food packaging and sustainable consumer goods. The expansion also aligns with Arkema's One Arkema strategy by strengthening the innovation ecosystem, including start-ups and emerging technology companies.
These investments are expected to reinforce Arkema's interaction with customers and support the development of solutions for high-growth markets, including new energy, electronics, mobility and sustainability. With Specialty Materials accounting for approximately 85% of its 2025 sales, the company's continued R&D investments support its strategic focus on becoming a world leader in Specialty Materials.
ARKAY shares have gained 4.2% in the past year compared with the industry’s 2.5% growth.
Image Source: Zacks Investment Research
ARKAY’s Zacks Rank & Key Picks
ARKAYcurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Cabot Corporation (CBT - Free Report) and Avient Corporation (AVNT - Free Report) .
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 49.7% over the past year.
The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%.CBTshares have gained 8.4% over the past year.
The Zacks Consensus Estimate for AVNT’s fiscal 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.
View the Zacks #1 Rank List
Image: Bigstock
Arkema Expands Shanghai R&D Center to Boost Innovation
Key Takeaways
Arkema S.A. (ARKAY - Free Report) has officially opened the expansion of its Shanghai R&D Center in China, strengthening its capabilities to foster innovation, enable synergies within teams and increase engagement with customers in Asia. The investment aligns with the company's global research and development strategy.
The expansion increases laboratory space by around 20% and introduces new collaborative facilities, including an interactive showroom to showcase Specialty Materials solutions. The upgraded center will bring together Arkema’s expertise in the materials business and interaction with the local R&D ecosystem to jointly develop with customers and accelerate innovation in high-performance and sustainable materials.
Established in 2011 as Bostik's Asia Technology Center, the Shanghai facility has developed expertise in materials synthesis, formulation development and application validation. Its innovations are used in high-speed rail, food packaging and sustainable consumer goods. The expansion also aligns with Arkema's One Arkema strategy by strengthening the innovation ecosystem, including start-ups and emerging technology companies.
These investments are expected to reinforce Arkema's interaction with customers and support the development of solutions for high-growth markets, including new energy, electronics, mobility and sustainability. With Specialty Materials accounting for approximately 85% of its 2025 sales, the company's continued R&D investments support its strategic focus on becoming a world leader in Specialty Materials.
ARKAY shares have gained 4.2% in the past year compared with the industry’s 2.5% growth.
Image Source: Zacks Investment Research
ARKAY’s Zacks Rank & Key Picks
ARKAYcurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Cabot Corporation (CBT - Free Report) and Avient Corporation (AVNT - Free Report) .
RS currently sports a Zacks Rank #1 (Strong Buy), while CBT and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 49.7% over the past year.
The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%.CBTshares have gained 8.4% over the past year.
The Zacks Consensus Estimate for AVNT’s fiscal 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.